GENE ONLINE|News &
Opinion
Blog

2022-06-30| Startups

US Bio-Entrepreneur Program Launches in the UK

by Joy Lin
Share To

Nucleate, a US-based non-profit organization dedicated to cultivating future biotech leaders, has announced its expansion into the UK, and will begin operations in London, Oxford, and Cambridge.

The venture has seen great interest among graduate scientific trainees and business students wanting to start a business in the biotech industry. Later this year, it will initiate a biotech accelerator program to educate and support aspiring students on their biotech journey. 

Related artice: Gilead Sciences Works Alongside Westminster Drug Project To Eliminate Hepatitis C 

 

Program Validation and Expansion 

 

Founded in 2019, Nucleate has validated its flagship accelerator program in 10 cities across the US, including Boston, San Francisco, New York, and Houston. Called the Activator program, it begins with grouping individual participants into teams, which will attend workshops. The teams also receive mentorships from a wide range of experts, including investors, academics and industry leaders. The efforts culminate in a final pitch showcase before a panel of judges. 

The program has birthed over 100 companies that have raised over $152 million in funding for projects such as protein sequencing (Glyphic), drug discovery (Manifold Bio), RNA synthesis (EnPlusOne) and microbial fertilizer (Ivu Biologics).

Nucleate has since stepped outside the US, launching in Switzerland and the UK, with additional incubators planned in other countries such as Israel and Japan. In the UK, the organization has plans to add additional locations beyond the existing three within a year. 

“I believe that Nucleate UK has the potential to transform the biotech entrepreneurship landscape in the United Kingdom” said Miroslav Gasparek, co-Managing Director of Nucleate UK.

The UK leadership team includes Stephanie Avraamides, Director of Operations, MPhil candidate at the University of Cambridge and Abhimanyu Gowda – Director of Strategy and BA candidate at the University of Cambridge.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Quince Therapeutics Overview for Strategic Growth
2022-08-01
Looking for the Exit; Startup Considerations and Strategies
2022-07-28
These Pharma Companies Are Laying Off Employees Due to Restructuring
2022-06-30
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!